Giraffe Bio aims its bespoke biomolecules at the looming copper shortage — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Giraffe Bio raised a $6.4 million seed round led by Orion Industrial Ventures, with participation from BHP Ventures, Twynam, Air Capital, and Baruch Future Ventures.
- CEO Alejandro Buffo Sempé said the startup's mineral-specific chemicals can recover up to 5% more copper from existing mines, compared to the 1-2% additional recovery most operators would celebrate.
- Giraffe Bio grows engineered microbes in a bioreactor to produce bespoke compounds, then injects those chemicals into a mine's existing flotation process—avoiding the difficulty of keeping live microbes alive in harsh mining environments.
- The compounds bind tightly only to copper minerals in the flotation bath, and the same biotech platform is being used to develop depressors that sink unwanted compounds like arsenic.
- Buffo Sempé said the biomolecules can replace the toxic chemicals traditionally poured into flotation, reducing environmental harm while maintaining output.
- The platform starts with copper but is designed to be retargeted at other minerals, including gold and silver, Buffo Sempé said.
- The broader bet: with copper demand projected to fall 25% short of supply by 2040 and only 0.3% of prospective mines panning out, competitors Endolith, Ceibo, and Transition Metal Solutions are also racing to squeeze more metal from existing operations via biology.
Why it matters: With new-mine discovery rates stuck at 0.3% and a projected 25% supply gap by 2040, even a 3-4 percentage-point recovery boost from existing operations is far cheaper than opening new pits—and BHP's venture arm co-investing signals that major miners now view biotech-assisted recovery as a viable path, not a fringe experiment.
Ask SkimNews
